April 20, 2018
Forty mph winds pelted cold rain against the runners as they approached the Boston Marathon’s infamous Heartbreak Hill. It was just before this mark that runner Courtney Duckworth’s eyesight started to blur. She couldn’t tell if her senses were warped from the terrible weather conditions or if it was something more serious. Living with Type 1 diabetes, she is used to keeping track of her health...
March 28, 2018
Yesterday Dexcom got the nod from the FDA to market their Dexcom G6, an integrated continuous glucose monitoring system (iCGM), making it the first interoperable CGM to get the designation.
“We are a company of firsts, almost everything that has been done in our industry has been done by us first,” Dexcom CEO Kevin Sayer told MobiHealthNews, citing that Dexcom was the first company to have a...
March 12, 2018
Medtronic has finally received FDA clearance for Guardian Connect, its smartphone-connected standalone CGM for patients who use multiple daily injections (MDI) for their insulin. Medtronic's closed-loop system for pump users was cleared in 2016.
"Despite proven benefits and advances in technology, only a minority of insulin-using people with diabetes currently use continuous glucose monitors (CGM...
February 26, 2018
The FDA has expanded its indication for Medtronic’s Guardian Sensor 3, allowing patients to wear the sensor on their upper arm.
The sensor is part of Medtronic’s MiniMed 670G system, and is currently the only continuous glucose monitor approved by the FDA to control automated insulin delivery via a hybrid closed loop system. Along with the added convenience of the new sensor site, the company...
February 21, 2018
Implantable glucose sensor company Senseonics has launched a remote monitoring app for its users in Europe, the Middle East, and Africa, where its CGM system is distributed by Roche.
The app, called Eversense Now, allows users of the sensor to select up to five friends or family members to view their glucose data, which is updated every five minutes. The feature is available for iOS users at the...
January 8, 2018
Fitbit has recently invested $6 million in San Fransisco-based Sano, a company developing a mobile app and sensor that will allow users to continuously monitor blood glucose levels, multiple publications have confirmed.
"This fits into our strategy of looking beyond the device and thinking more about (health) solutions,” Fitbit CEO James Park told CNBC. "I think the complete solution comes in...
November 1, 2017
Implantable continuous glucose monitor (CGM) maker Senseonics is still making the long trudge toward FDA clearance, but at least the company has plenty of European activity to keep it occupied in the meantime.
On a Q3 earnings call, CEO Timothy Goodnow shared details on his company’s continued ramp-ups and rollouts across Europe, its first entry into an international market, and the receipt of a...
September 27, 2017
Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to the US where Abbott is based, the approval also represents a first for continuous glucose monitoring, as it doesn't require the user to use a fingerstick, even for calibration.
"From an emotional...
September 7, 2017
Good news for anyone who thought Fitbit's move toward the smartwatch market would be a move away from health: The wearable maker has just announced a partnership with Dexcom that will bring data from the company's continuous glucose monitor directly to the display of Fitbit's upcoming Ionic smartwatch.
Athough Fitbit's have been used in the management of chronic diseases in a number of hospital...
August 21, 2017
A new study published today in Annals of Internal Medicine and sponsored by Dexcom shows that a continuous glucose monitor could lower the HbA1c scores of people with Type 2 diabetes, and that acceptance of the technology is high among that group as well.
Right now, continuous glucose monitoring is a technology mostly used by people with Type 1 diabetes, many of whom administer insulin via an...